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Introduction to World Kidney Day 2011
March 10, 2011 will mark the celebration of the 6th World Kidney Day
(WKD), an annual event jointly sponsored by the International Society of
Nephrology and the International Federation of Kidney Foundations. Since
its inception in 2006, WKD has grown dramatically to become the most
widely celebrated event associated with kidney disease in the world and
the most successful effort to raise awareness among both the general
public and government health officials about the dangers of kidney disease,
especially chronic kidney disease (CKD). 
In 2011, WKD will call attention to the large, and often unappreciated,
role played by kidney dysfunction in increasing premature cardiovascular
disease, the most common cause of morbidity and mortality worldwide [1].
Can a focus on early detection and prevention of kidney disease really
improve long term cardiovascular health? In this editorial, we hope to
convey the message that increased attention to the kidneys can indeed
improve  long-term  health  outcomes  by  reducing  both  kidney  and
cardiovascular disease and should therefore be a central component of
any global health strategy intended to reduce the enormous and growing
burden of chronic non-comunicable diseases (NCDs).
Cardiovascular disease and the kidney
Cardiovascular disease (CVD) is the most common of the chronic NCDs
that impact global mortality. About 30% of all deaths worldwide and 10%
of all healthy life lost to disease are accounted for by CVD alone [1].
Although there has been some decline in mortality from CVD in developed
countries, no such decline has been reportedin developing countries, ethic
and  socially  disadvantaged  minority  populations  or  in  people  with
accompanying CKD [2, 3].
The presence of CKD significantly increases the risk of a CV event in
both diabetes and hypertension [4, 5]. However, less well appreciated is
that CKD alone is a strong risk factor for CVD, independent of diabetes,
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hypertension or any other conventional CVD risk
factor [6, 7]. This is especially true when an increase
in proteinuria, a major target of any CKD screening
program, is present [6-9]. 
The 20-30-fold increase in CVD in patients with
ESRD has long been recognized, but the increased
risk for CVD associated with lesser degrees of 
renal  functional  impairment  was  definitively
demonstrated only in 2004. Go et al reported an
independent and graded association between GFR
and risk of death, CV events and hospitalizations
was reported in a community-based study of over
1.1 million individuals [6]. 
Is this dramatic increase in CVD risk associated
with CKD really due to CKD or does it just reflect
the coexistent diabetes or hypertension that are
present  in  a majority  of  these  patients?  The
independent effect of CKD alone has now been well
documented in many studies [7], with one study in
a high risk populationshowing that the risk of
cardiac death is increased 46% in those with a GFR
between 60 and 90 ml/min and 131% in those with
GFR between 30 and 60 ml/min, independent of
traditional CV risk factors including diabetes and
hypertension [10]. The increased risk for CV events
and mortality in people over 55 with CKD alone is
equivalent, or even higher, to that seen in patients
with diabetes or previous myocardial infarcts [11].
Both general [6, 12] and high-risk populations [13,
14] exhibit an increased risk of CVD with CKD. This
increased risk for CVD is not confined to the elderly
– in volunteers with an average age of 45, the risk
for myocardial infarct, stroke and all cause mortality
was doubled in those with CKD [14]. 
Proteinuria and cardiovascular risk
In  considering  the  value  of  recommending
screening for CKD along with conventional CVD risk
factors in selected individuals data showing that
the risk of CVD is better correlated with proteinuria
(albuminuria) than with GFR alone is particularly
relevant because proteinuria is virtually always
a marker of kidney disease and is not a con  -
ventional CVD risk factor [6, 8, 9, 15].
With regard to proteinuria as a predictor of later
CVD, the PREVEND study showed a direct linear
relationship between albuminuria and risk of CV
death in the general population even at levels of
albumin excretion generally considered within the
“normal” range (15-29 mg/day) and was increased
more than 6 fold when albumin excretion exceeded
300 mg/day [8]. 
Recent data from the US NHANES database as
well as from Japan also document an independent
effect of albuminuria on risk of both CVD and all
cause mortality at all levels of GFR [15, 16]. In
patients with congestive heart failure but without
diabetes, hypertension, increased urinary albumin
predicts both CV and all cause mortality inde  -
pendent  of  reduced  GFR  [17].  Similar  results 
are  obtained  studying  patients  with  coronary
disease or previous myocardial infarcts in whom
proteinuria conferred a greater risk of mortality than
reduced GFR, although both adversely impacted
outcomes [18].
Of interest, not only the likelihood but also the
time to development of a CV event is accelerated
significantly by the presence of proteinuria at all
levels of GFR [19]. In non-diabetic subjects with
normal  serum  creatinine  levels  undergoing
percutaneous coronary interventions, about 78%
have  demonstrable  CKD  when  screened  more
stringently for eGFR and urine protein [20]. Not only
is the presence of CKD a likely factor in accelerating
development of coronary disease in these patients
but it has also been associated with an increase in
other risks including hemorrhagic complications,
contrast nephropathy, re-stenosis, and death [10].
Thus multiple studies now confirm that proteinuria
is a graded risk factor for CVD independent of GFR,
hypertension  and  diabetes  and  that  this  risk
extends down into ranges of albumin excretion
generally considered “normal” [21, 22]. Moreover,
this increased CV risk has been well demonstrated
in several studies where only dipsticks were used
to screen for increased protein excretion [6, 18, 23].
Although  there  has  been  concern  that  CKD
diagnosed  by  reduced  GFR  alone  identifies
predominately  older  adults  at  increased  risk
because of age alone [24], the connection between
proteinuria as an independent risk factor for CV
mortality has been confirmed by meta-analysis of
22 separate, general population, cohort studies and
in both older (> 65) and younger people of several
nationalities and racial groups [23].
Can treatment of chronic kidney disease reduce
cardiovascular disease?
Finally, and most importantly from a clinical
perspective, there is provocative data to suggest
that  renal-targeted  interventions  designed  to
reduce proteinuria and slow progression of CKD can
reduce CVD risk as well. ACEI and/or ARBs are of
documented benefit in slowing progression of
established diabetic and non-diabetic CKD [25-29].
Of interest related to slowing progression, the
incidence of CVD in CKD is significantly higher with
more rapid loss of GFR independent of other risk
factors, suggesting that interventions that slow
progression may also reduce CVD [19]. PREVEND IT
reported a 40% (but not significant) reduction in CV
events over 4 years in patients screened from
a general population with no risk factors except
increased albumin in the urine who were treated
with ACEI therapy [30]. In this pilot study, this effect
was most notable in people with albumin excretionArch Med Sci 1, February / 2011 3
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rates of > 50 mg/day; furthermore, a post hoc cost-
effectiveness analysis noted that the intervention
is likely cost effective in that population [31]. In the
RENNAL study, CV endpoints were significantly
reduced in direct proportion to the reduction of
albuminuria with ACEI therapy in type 2 diabetics,
and albuminuria proved to be the only predictor of
CV outcome [32]. The potential benefit of renal-
targeted therapies has recently been highlighted
by  observations  that  higher  doses  of  renin-
angiotensin system (RAS) blockers than required
for BP control alone can further reduce proteinuria
independent of effects on BP or GFR, and that
addition of salt restriction or diuretics, both very
inexpensive interventions, can further enhance the
proteinuria-reducing effect of RAS blockade [33, 34].
Data  are  not  yet  available  to  establish  that
screening for CKD and subsequent interventions
will reduce CV mortality and be cost-effective in
younger people (< 55) [35]. However, it is now
known that albuminuria is a better predictor of
renal and cardiovascular events than blood pressure
alone, that reducing proteinuria is more renal and
cardio protective than lowering blood pressure
aloneand that identification of CKD can improve CV
outcomes. 
Conclusions
As celebrations of the sixth World Kidney Day
approach on March 10, 2011, it is worth noting that
prior to the past decade, kidney disease was seen
by most government and public health authorities
as largely confined to patients with ESRD, thankfully
a rare condition because the enormous cost of renal
replacement therapy disproportionately consumes
scarce health care resources and is well beyond the
means of countries inhabited by over 80% of the
worlds population [36, 37]. Much has changed. We
now appreciate that kidney disease is not rare –
some 10% of the population has evidence of renal
dysfunction. And we know these individuals are not
of concern just because a few will progress to ESRD,
but more because they carry a greatly enhanced
risk of premature death from CVD, the single largest
and most expensive health care threat we confront
at a global level [1]. Just as progress is being made
in treating most of the traditional CV risk factors,
CKD has emerged as yet another one that causes
substantial  vascular  toxicity  independently.
Fortunately, there is good news as well. Biomarkers
of CKD (proteinuria, eGFR) are easy and relatively
inexpensive to detect, and one of these, proteinuria,
emerges  early  in  the  evolution  of  generalized
vascular disease. Thus kidney-targeted detection
and prevention programs seem to offer a valuable
opportunity to institute early preventive measures
that  go  beyond  traditional  cardio-protective
approaches. There is now compelling evidence that
including selective screening for CKD in global
health programs designed primarily to reduce CVD
will significantly improve the outcomes of not only
renal disease, but especially the NCDs like diabetes
and  CVD  that  dominate  future  health  care
strategies. Roadmaps for accomplishing this have
already been presented for both developed [38, 39]
and emerging [1, 40] countries. However, effective
implementation of such strategies will only come
when  both  the  general  public  and  the  renal
community  work  together  to  convince  health
authorities it is in the public interest to do this. It
is our sincere hope that worldwide celebration of
World Kidney Day 2011 will provide an opportunity
to reinforce the message that kidney disease is
indeed common, harmful and treatable and that
protecting your kidneys is an important health
strategy that may save your heart.
References
1. World Health Organization. Preventing Chronic Diseases:
A Vital Investment: WHO global report. 2005. 2008-2013
action plan for the global strategy for the prevention and
control of noncommunicable diseases: prevent and control
cardiovascular diseases, cancers, chronic respiratory
diseases and diabetes.
2. Anderson GF, Chu E. Expanding priorities – confronting
chronic disease in countries with low income. N Engl 
J Med 2007; 356: 209-11. 
3. Narayan KM, Ali MK, Koplan JP . Global noncommunicable
diseases – where worlds meet. N Engl J Med 2010; 363:
1196-8.
4. Ritz E, Bakris G; World Kidney Day Organising Committee.
World Kidney Day: hypertension and chronic kidney
disease. Lancet 2009; 373: 1157-8. 
5. Atkins RC, Zimmet P, ISN-IFKF World Kidney Day Steering
Committee. Diabetic kidney disease: act now or pay later.
Nat Rev Nephrol 20120; 6: 134-6.
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic
kidney disease and the risks of death, cardiovascular
events, and hospitalization. N Engl J Med 2004; 351: 
1296-305. 
7. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney
disease and mortality risk: A systematic review. J Am Soc
Nephrol 2006; 17: 2034-47. 
8. Hillege HL, Fidler V, Diercks GFH, et al.; for the PREVEND
studygroup. Urinary albumin excretion predicts cardio  -
vascular and noncardiovascular mortality in general
population. Circulation 2002; 106: 1777-82. 
9. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al.
Very low levels of microalbuminuria are associated with
increased risk of coronary heart disease and death
independently  of  renal  function,  hypertension,  and
diabetes. Circ 2004; 110: 32-5.
10. van Domburg RT, Hoeks SE, Welten GMJM, Chonchol M,
Elhendy  A,  Poldermans  D.  Renal  insufficiency  and
mortality in patients with known or suspected coronary
artery disease. J Am Soc Neph 2008; 19: 158-63. 
11. Rashidi A, Sehgal AR, Rahman M, O'Connor AS. The case
for chronic kidney disease, diabetes mellitus, and myo  -
cardial infarction being equivalent risk factors for car  -
diovascular mortality in patients older than 65 years. Am
J Cardiol 2008; 102: 1668-7. 4 Arch Med Sci 1, February / 2011
William G. Couser, Miguel C. Riella
12. McCullough PA, Li S, Jurkovitz CT, et al.; Kidney Early
Evaluation Program Investigators. CKD and Cardiovascular
Disease in Screened High-Risk Volunteer and General
Populations: The Kidney Early Evaluation Program (KEEP)
and National Health and Nutrition Examination Survey
(NHANES) 1999-2004. Am J Kidney 2008; Ds51: S38-S45. 
13. McCullough PA, Jurkovitz CT, Pergola PE, et al.; for the KEEP
Investigators. Independent components of chronic kidney
disease as a cardiovascular risk state: results from the
Kidney Early Evaluation Program (KEEP). Arch Intern Med
2007; 167: 1122-9. 
14. McCullough PA, Li S, Jurkovitz CT, et al.; KEEP Investigators.
Chronic  kidney  disease:  prevalence  of  premature
cardiovascular disease and relationship to short-term
mortality. Am Heart J 2008; 156: 277-83.
15. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J.
Glomerular  filtration  rate,  albuminuria,  and  risk  of
cardiovascular  and  all-cause  mortality  in  the  US
population. Am J Epidemiol 2008; 167: 1226-33. 
16. Irie F, Iso H, Sairenchi T, et al. The relationships of pro  -
teinuria, serum creatinine, glomerular filtration rate with
cardiovascular disease mortality in Japanese general
population. Kidney Int 2006; 69: 1264-71. 
17. Jackson CE, Solomon SD, Gerstein HC, et al.; CHARM
Investigators and Committees. Albuminuria in chronic
heart failure: prevalence and prognostic importance.
Lancet 2009; 374: 543-50. 
18. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer
M;  Cholesterol  and  Recurrent  Events  (CARE)  Trial
Investigators. Proteinuria, impaired kidney function, and
adverse outcomes in people with coronary disease:
analysis of a previously conducted randomisedtrial. BMJ
2006; 332: 1426. 
19. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC,
Coresh J. Change in estimated GFR associates with
coronary heart disease and mortality. J Am Soc Nephrol
2009; 20: 2617-24. 
20. Malyszko J, Bachorzewska-Gajewska H, Malyszko JS,
Dobrzycki S. Prevalence of chronic kidney disease in
elderly patients with normal serum creatinine levels
undergoing  percutaneous  coronary  interventions.
Gerontol 2010; 56: 51-4. 
21. Hemmelgarn BR, Manns BJ, Lloyd A, et al.; Alberta Kidney
Disease  Network.  Relation  between  kidney  function,
proteinuria, and adverse outcomes. JAMA 2010; 303: 423-9.
22. Gansevoort RT, de Jong PE. The case for using albuminuria
in staging chronic kidney disease. J Amer Soc Nephrol
2009; 20: 465-8. 
23. Chronic Kidney Disease Prognosis Consortium. Association
of estimated glomerular filtration rate and albuminuria
with all-cause and cardiovascular mortality in general
population cohorts: a collaborative meta-analysis. Lancet
2010; 375: 2073-81. 
24. Abdelhafiz AH, Brown SH, Bello A, El Nahas M. Chronic
kidney disease in older people: physiology, pathology or
both? Nephron Clin Pract 2010; 116: 19-24.
25. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study
Investigators. Effects of losartan on renal and car  dio  -
vascular outcomes in patients with type 2 diabetes and
nephropathy. N Engl J Med 2001; 345: 861-9.
26. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective
properties of ACE-inhibition in non-diabetic nephropathies
with non-nephrotic proteinuria. Lancet 1999; 354: 359-64.
27. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R,
Remuzzi G. Renal function and requirement for dialysis in
chronic nephropathy patients on long-term ramipril: REIN
follow-up trial. Gruppo Italiano di Studi Epidemiologici in
Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.
Lancet 1998; 352: 1252-6. 
28. The GISEN Group (Gruppo Italiano di Studi Epidemiologici
in Nefrologia). Randomised placebo-controlled trial of
effect of ramipril on decline in glomerular filtration rate
and risk of terminal renal failure in proteinuric, non-
diabetic nephropathy. Lancet 1997; 349: 1857-63. 
29. The ESCAPE trial group. Strict blood pressure control and
progression of renal failure in children. New Engl J Med
2009; 361: 1639-50. 
30. Asselbergs FW, Diercks GF, Hillege HL, et al.; Prevention
of Renal and Vascular Endstage Disease Intervention Trial
(PREVEND IT) Investigators. Effects of fosinopril and
pravastatin on cardiovascular events in subjects with
microalbuminuria. Circulation 2004; 110: 2809-16. 
31. Atthobari J, Asselbergs FW, Boersma C, et al.; PREVEND IT
Study  Group.  Cost-effectiveness  of  screening  for
albuminuria with subsequent fosinopril treatment to
prevent cardiovascular events: A pharmacoeconomic
analysis linked to the prevention of renal and vascular
endstage disease (PREVEND) study and the prevention of
renal and vascular endstage disease intervention trial
(PREVEND IT). Clin Ther 2006; 28: 432-44. 
32. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is
a target for renoprotective therapy independent from blood
pressure in type II diabetic patients with nephropathy. Post
hoc analysis from the Reduction in End Points in NIDDM
with the Angiotensin II Antagonist Losartan (RENAAL) trial.
J Am Soc Nephrol 2007; 18: 1540-6. 
33. Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S;
SMART (Supra Maximal Atacand Renal Trial) Investigators.
Supramaximal dose of candesartan in proteinuric renal
disease. J Am Soc Nephrol 2009; 20: 893-900. 
34. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G.
Effects of dietary sodium and hydrochlorothiazide on the
antiproteinuric efficacy of losartan. J Am Soc Nephrol
2008; 19: 999-1007. 
35. Fried L. Are we ready to screen the general population for
microalbuminuria? J Am Soc Nephrol 2009; 20: 686-8. 
36. El Nahas M. The global challenge of chronic kidney
disease.  (Nephrology  Forum).  Kidney  Int  2005;  68: 
2918-29.
37. Barsoum RS. Chronic kidney disease in the developing
world. New Engl J Med 2006; 354: 997-9. 
38. Levey AS, Schoolwerth AC, Burrows NR, Williams DE, 
Stith KR, McClellan W; Centers for Disease Control and
Prevention Expert Panel. Comprehensive public health
strategies for preventing the development, progression,
and complications of CKD: report of an expert panel
convened  by  the  Centers  for  Disease  Control  and
Prevention. Am J Kidney Dis 2009; 53: 522-35. 
39. James MT, Hemmelgarn BR, Tonelli M. Early recognition
and prevention of CKD. Lancet 2010; 379: 1296-309.
40. Perico N, Bravo RF, De Leon FR, Remuzzi G. Screening for
chronic kidney disease in emerging countries: feasibility
and hurdles. Nephrol Dial Transplant 2009; 24: 1355-8. 